Nature Communications (Sep 2022)
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
- Wu-tong Ju,
- Rong-hui Xia,
- Dong-wang Zhu,
- Sheng-jin Dou,
- Guo-pei Zhu,
- Min-jun Dong,
- Li-zhen Wang,
- Qi Sun,
- Tong-chao Zhao,
- Zhi-hang Zhou,
- Si-yuan Liang,
- Ying-ying Huang,
- Yong Tang,
- Si-cheng Wu,
- Jing Xia,
- Shi-qing Chen,
- Yue-zong Bai,
- Jiang Li,
- Qi Zhu,
- Lai-ping Zhong
Affiliations
- Wu-tong Ju
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Rong-hui Xia
- Department of Oral Pathology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Dong-wang Zhu
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Sheng-jin Dou
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Guo-pei Zhu
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Min-jun Dong
- Department of Radiology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Li-zhen Wang
- Department of Oral Pathology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Qi Sun
- Department of Radiology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Tong-chao Zhao
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Zhi-hang Zhou
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Si-yuan Liang
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Ying-ying Huang
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Yong Tang
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Si-cheng Wu
- Biostatistics Office of Clinical Research Unit, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Jing Xia
- The Medical Department, 3D Medicines Inc.
- Shi-qing Chen
- The Medical Department, 3D Medicines Inc.
- Yue-zong Bai
- The Medical Department, 3D Medicines Inc.
- Jiang Li
- Department of Oral Pathology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Qi Zhu
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- Lai-ping Zhong
- Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33080-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
In patients with locally advanced resectable oral squamous cell carcinoma (OSCC), the risk of recurrence and metastasis following treatment is high. Here, a phase I clinical trial reports safety and pathological response of neoadjuvant camrelizumab and apatinib in patients with locally advanced resectable OSCC.
